Without getting compromisingly specific: there are tables in there.
They are one-way: what of MDR and IVDR is (partly) covered by 14971:2019. You must still check GSPR versus these for complete coverage to have clear demonstration of risk mgt compliance.
The part things specifically excludes device-specific aspects and usability (62366-*).
Unmentioned as not covered by presumption of compliance seem to be 1 (acceptable risk as weighed etc), 2 (not stated as needing to inform risk acceptability policy of the standard, which is odd vs how it was done for the 2012 one), 6 (normal use effect over lifetime of device) and 7 (transport and storage).
Nothing of annex 1 chapter ii, thus also missing biological evaluation aspects, sterility, etc. (Annex 1 chapter 1 doesn't call out to chapter 2, so it isn't covered by calling it in from something in the table).
Furthermore it makes the same deadly assumption of being able to 1:1copy-overwrite the definitions for terms of the standard with the definitions from the regulation as the previous one, except for the now whopping 7 reduction policies which are barely meaningfully distinguishable, yet that need to be implemented as if they were.
There's also a note (which cannot contain requirements) requiring things no other part of the main body makes requirements on (which at least tries to reach chapter 2).
I know/presume this cannot be easy work to get right and get consensus on, but its current shape is a formality and not a help/boon to anybody, whether manufacturer, patient, user or inspecting body. It doesn't add anything over 14971, nor technically ensure all appropriate risk mgt is declared.
Note: no rights can be derived from my above statement for technical file review commentary or audits (obviously).
Edit: god one can make many typos when typing on mobile. Fixed most (probably)